Generic Daytrana Availability

Daytrana is a brand name of methylphenidate, approved by the FDA in the following formulation(s):

DAYTRANA (methylphenidate - film, extended release;transdermal)

  • Manufacturer: NOVEN PHARMS INC
    Approval date: April 6, 2006
    Strength(s): 10MG/9HR (1.1MG/HR), 15MG/9HR (1.6MG/HR), 20MG/9HR (2.2MG/HR), 30MG/9HR (3.3MG/HR) [RLD]

Has a generic version of Daytrana been approved?

No. There is currently no therapeutically equivalent version of Daytrana available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Daytrana. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
    Patent 6,210,705
    Issued: April 3, 2001
    Inventor(s): Mantelle; Juan & Dixon; Terese A.
    Assignee(s): Noven Pharmaceuticals, NC.
    The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours.
    Patent expiration dates:
    • September 30, 2018
      ✓ 
      Patent use: FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
      ✓ 
      Drug product
  • Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
    Patent 6,348,211
    Issued: February 19, 2002
    Inventor(s): Juan; Mantelle & Terese A.; Dixon
    Assignee(s): Noven Pharmaceuticals, Inc.
    The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours.
    Patent expiration dates:
    • September 30, 2018
      ✓ 
      Patent use: FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
      ✓ 
      Drug product
  • Device for transdermal administration of drugs including acrylic polymers
    Patent 8,632,802
    Issued: January 21, 2014
    Assignee(s): Noven Pharmaceuticals, Inc.
    A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent.
    Patent expiration dates:
    • October 7, 2025
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web3)